You are here: Industry Insights > acquisition

News List

Endo International agrees to acquire BioSpecifics Technologies for $540m pharmaceutical-technology
October 22, 2020
Endo International has agreed to acquire BioSpecifics Technologies in a cash-based transaction valued at approximately $540m.
UCB acquires new campus to support UK operations pharmatimes
October 22, 2020
Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.
Powder Flow:MICROMERITICS INSTRUMENT CORP. ACQUIRES FREEMAN TECHNOLOGY Freeman Technology
October 21, 2020
Micromeritics Instrument Corporation, a leading global manufacturer of premium products for advanced material characterisation, today announced the acquisition of Freeman Technology.
Astellas to acquire iota Biosciences following R&D partnership pharmatimes
October 19, 2020
Japanese pharma Astellas will acquire bioelectronics firm iota after announcing a research and development agreement last year.
Eli Lilly to acquire biotechnology company Disarm Therapeutics pharmaceutical-technology
October 19, 2020
Eli Lilly has entered a definitive agreement to acquire biotech firm Disarm Therapeutics for an upfront payment of $135m.
HitGen to acquire Vernalis for $25 mn in cash expresspharma
October 14, 2020
The closing of this transaction is subject to customary conditions and approvals, expected to complete before the end of 2020.
Sanofi concludes acquisition of Principia Biopharma expresspharma
October 09, 2020
The Principia acquisition strengthens Sanofi’s core areas of autoimmune and allergic diseases.
Permira to acquire German pharma firm Neuraxpharm pharmaceutical-technology
September 27, 2020
Private equity firm Permira has agreed to acquire German speciality pharmaceutical company Neuraxpharm from Apax Partners.
Viva Biotech and SYNthesis Enter Strategic Acquisition Agreement contractpharma
September 22, 2020
Accelerates Viva’s development of global innovative drug R&D service capabilities.
Gilead agrees to acquire Immunomedics for $21bn pharmaceutical-technology
September 15, 2020
Gilead Sciences has signed a definitive agreement to acquire cancer therapies developer Immunomedics for a total consideration of approximately $21bn, or $88 per share.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page